Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 5/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 3/20 | 0.37 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | HTR2B | P41595 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24278585 | 1.00 | CA2 (0.46) | CA2GSRKDM1AKDM1BMAOA | |
| SCHEMBL14668118 | 1.00 | CA2 (0.46) | CA2GSRKDM1AKDM1BMAOA | |
| SCHEMBL27053504 | 1.00 | CA2 (0.46) | CA2GSRKDM1AKDM1BMAOA | |
| SCHEMBL25796805 | 1.00 | CA2 (0.46) | CA2GSRKDM1AKDM1BMAOA | |
| SCHEMBL3038872 | 1.00 | CA2 (0.46) | CA2GSRKDM1AKDM1BMAOA | |
| SCHEMBL27053505 | 0.83 | CA2 (0.38) | CA2GSRKDM1AKDM1BMAOA | |
| SCHEMBL25796871 | 0.83 | CA2 (0.38) | CA2GSRKDM1AKDM1BMAOA | |
| SCHEMBL25796248 | 0.80 | KDM1A (0.35) | CA2GSRKDM1AHTR2CHTR2B | |
| SCHEMBL24278729 | 0.80 | KDM1A (0.35) | CA2GSRKDM1AHTR2CHTR2B | |
| SCHEMBL12405329 | 0.78 | KDM1A (0.41) | CA2GSRKDM1AKDM1BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | claimed |
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | claimed |
| EP-2334679-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Actavis Group PTC EHF (IS) | 2011-06-22 | — | — | EP | claimed |
| WO-2010023561-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-03-04 | — | — | WO | claimed |
| US-20090318695-A1 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-24 | — | — | US | claimed |
| WO-2009155403-A2 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-12-23 | — | — | WO | claimed |
| EP-4206182-A1 | ESTER COMPOUND | Mitsui Chemicals, Inc. (JP) | 2023-07-05 | — | — | EP | disclosed |
| WO-2022045231-A1 | ESTER COMPOUND | 三井化学株式会社 | 2022-03-03 | — | — | WO | disclosed |
| WO-2018163190-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF VARENICLINE AND SALT THEREOF | JUBILANT GENERICS LIMITED (FORMERLY A DIVISION OF JUBILANT LIFESCIENCES LIMITED) (IN) | 2018-09-13 | — | — | WO | disclosed |
| EP-1044189-B2 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2015-02-25 | — | — | EP | disclosed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | disclosed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | disclosed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | disclosed |
| EP-1259489-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020132824-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2002-09-19 | — | — | US | disclosed |
| US-20020111350-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2002-08-15 | — | — | US | disclosed |
| US-6410550-B1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-25 | — | — | US | disclosed |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2002-06-13 | — | — | US | disclosed |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | WADSWORTH JOTHAM (US) | 2002-06-13 | — | — | US | disclosed |
| WO-2001062736-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | CA2 667/4885GSR 1512/4885KDM1A 208/4885 |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | CA2 667/4885GSR 1512/4885KDM1A 208/4885 |
| US-20020132824-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | CA2 4141/4885GSR 1617/4885KDM1A 660/4885 |
| US-20020072524-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | CA2 4141/4885GSR 1617/4885KDM1A 660/4885 |
| US-20090318695-A1 | PROCESSES FOR THE PREPARATION OF VARENICLINE AND INTERMEDIATES THEREOF | COMT, CYP3A7, CHRNA7 | CA2 3044/4885GSR 473/4885KDM1A 708/4885 |
| US-20020111350-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | CA2 4141/4885GSR 1617/4885KDM1A 660/4885 |
| US-20020072525-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN2B | CA2 4141/4885GSR 1617/4885KDM1A 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.